Get the Weekly Intelligence Brief — top committee picks every Sunday.

ACAD vs IRTC

ACADIA Pharmaceuticals Inc. vs iRhythm Technologies, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
IRTC
iRhythm Technologies, Inc.
58
Watch
MetricACADIRTC
AI Score 69 58
Price $29.41 $121.80
P/E Ratio 13.07× -283.42×
ROE 31.9% -29.2%
Revenue Growth YoY
Gross Margin 91.1% 71.5%
Debt / Equity 0.06× 3.91×
Dividend Yield 0.0% 0.0%
RSI (14) 78.4 50.5
Beta 0.845 1.321
Expected Upside

AI Committee View

Current Innellis committee reasoning for ACAD versus IRTC.
ACAD leads by 11 points.

ACAD scores 69/100 (Buy) versus IRTC at 58/100 (Watch).

ACAD Committee View
83% agreement
6 analysts

The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull Case
  • P/E of 13.2 is inexpensive for the broad market — Value
  • ROE of 32.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
  • RSI at 78 is in overbought territory — Technical
  • Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 24.3% signals elevated volatility — Risk
IRTC Committee View
50% agreement
6 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 27.4% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 37.4x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Revenue growing 27.4% YoY -- genuine top-line momentum — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • Price-to-book of 37.4x prices in significant intangible value — Value
  • ROE of only -20.6% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 4.25 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ACAD Full Analysis IRTC Full Analysis